Research progress on targeted drugs and its applications in the treatment of keloids

Abstract

Keloid (KD) is a pathological scar caused by excessive proliferation of fibroblasts and excessive deposition of extracellular matrix (ECM) in the skin during wound repair. It is often complicated with pain and pruritus, which can seriously affect the quality of life of patients. Although various treatments, such as injections, lasers, and surgeries, are available, the outcome is not satisfactory. Therefore, targeted therapeutic regimens, including a large molecule monoclonal antibody (Dupilumab) and the small molecule targeted drugs (Nintedanib, Sorafenib and Sunitinib), have been deployed to treat keloids. This review summarizes the progress on the treatment of keloids with these targeted drugs and their applications in the future.

Keywords

• keloid
• targeted drug
• dupliumab
• nintedanib
• sunitinib
• sorafenib